Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Regorafenib Maintenance for Sarcoma
Double-blind, placebo-controlled, randomized phase 2 trial (EREMISS) Advanced non-adipocytic soft tissue sarcomas post 1st-line doxorubicin-based chemotherapy Regorafenib 120 mg/da
New Indication: Nivolumab – Ipilimumab for Neoadjuvant NSCLC
Phase 3, randomized, open-label trial (CheckMate 816) Stage IB-IIIA resectable NSCLC Neoadjuvant nivolumab + ipilimumab vs. chemotherapy
New Protocol: Eribulin with Trastuzumab-Pertuzumab in First-Line Breast Cancer
Phase 3, randomized, open-label, noninferiority trial (EMERALD) HER2+ locally advanced/metastatic breast cancer Eribulin + trastuzumab + pertuzumab vs. Taxane (docetaxel or paclita
New Protocol: Metronomic Capecitabine with Aromatase Inhibitors in Metastatic Breast Cancer
Randomized, open-label, phase 3 trial (MECCA) HR+/HER2- metastatic breast cancer, treatment-naive in metastatic setting Metronomic capecitabine (500 mg TID continuously) + AI vs. A
New Reference: Botensilimab / Balstilimab for Metastatic Sarcomas
Phase 1, open-label, multicenter study (C-800-01) Patients with relapsed/refractory metastatic sarcomas Botensilimab (1 or 2 mg/kg IV Q6W) + Balstilimab (3 mg/kg IV Q2W) for up to
New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations
Open-label, randomized, multicenter phase 3 trial (ACHILLES/TORG1834) Previously untreated non-squamous NSCLC with sensitizing uncommon EGFR mutations (excluding exon20ins and T790
New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations
Phase II, single-arm, open-label study (TROPION-Lung05) Advanced/metastatic NSCLC with actionable genomic alterations Datopotamab deruxtecan 6mg/kg Q3W
New Reference: Sacituzumab Govitecan for Advanced Urothelial Carcinoma
Phase 3, randomized, open-label trial (TROPiCS-04) Previously treated advanced urothelial carcinoma (progression after platinum-based chemotherapy and checkpoint inhibitor) Sacituz
New Reference: Ipilimumab / Nivolumab for Non-Clear Cell RCC
Phase 2, multicenter, randomized trial (SUNNIFORECAST) Previously untreated advanced/metastatic non-clear cell RCC Ipilimumab + nivolumab (4 cycles) followed by nivolumab maintenan
